Song M - Search Results

1

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.

Griffiths CEM, Papp KA, Song M, Miller M, You Y, Shen YK, Han C, Blauvelt A. Griffiths CEM, et al. Among authors: song m. J Dermatolog Treat. 2022 Mar;33(2):848-856. doi: 10.1080/09546634.2020.1782817. Epub 2020 Jul 13. J Dermatolog Treat. 2022. PMID: 32660282 Free article. Clinical Trial.

2

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.

Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM. Gordon KB, et al. Among authors: song m. Br J Dermatol. 2018 Jan;178(1):132-139. doi: 10.1111/bjd.16008. Epub 2017 Dec 14. Br J Dermatol. 2018. PMID: 28940259 Clinical Trial.

3

Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.

Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K. Gordon KB, et al. Among authors: song m. J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1940-1949. doi: 10.1111/jdv.15012. Epub 2018 Jul 18. J Eur Acad Dermatol Venereol. 2018. PMID: 29706008 Clinical Trial.

4

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.

Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB. Reich K, et al. Among authors: song m. Br J Dermatol. 2019 May;180(5):1039-1049. doi: 10.1111/bjd.17454. Br J Dermatol. 2019. PMID: 30485400 Clinical Trial.

5

Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study.

Li N, Teeple A, Muser E, You Y, Song M, Armstrong AW. Li N, et al. Among authors: song m. J Dermatolog Treat. 2022 Feb;33(1):278-283. doi: 10.1080/09546634.2020.1750552. Epub 2020 Apr 16. J Dermatolog Treat. 2022. PMID: 32233940 Free article. Clinical Trial.

6

Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.

Puig L, Tsai TF, Bhutani T, Uy J, Ramachandran P, Song M, You Y, Gooderham M, Lebwohl M. Puig L, et al. Among authors: song m. J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1744-1749. doi: 10.1111/jdv.16460. Epub 2020 May 15. J Eur Acad Dermatol Venereol. 2020. PMID: 32289190 Clinical Trial.

7

Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.

Armstrong A, Puig L, Langley R, Tsai TF, Song M, Wasfi Y, Jiang J, Li S, Han C. Armstrong A, et al. Among authors: song m. J Dermatolog Treat. 2019 Feb;30(1):27-34. doi: 10.1080/09546634.2017.1364694. Epub 2018 Sep 24. J Dermatolog Treat. 2019. PMID: 28797188 Free article. Clinical Trial.

8

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.

Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Foley P, et al. Among authors: song m. JAMA Dermatol. 2018 Jun 1;154(6):676-683. doi: 10.1001/jamadermatol.2018.0793. JAMA Dermatol. 2018. PMID: 29799960 Free PMC article. Clinical Trial.

9

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Griffiths CEM, et al. Among authors: song m. J Drugs Dermatol. 2018 Aug 1;17(8):826-832. J Drugs Dermatol. 2018. PMID: 30124721 Clinical Trial.

10

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.

Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA. Armstrong AW, et al. Among authors: song m. Am J Clin Dermatol. 2019 Feb;20(1):155-164. doi: 10.1007/s40257-018-0396-z. Am J Clin Dermatol. 2019. PMID: 30417277 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,328 results

Search Page

Filters